Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Contineum Therapeutics (CTNM) Non-Current Assets (2023 - 2025)

Contineum Therapeutics (CTNM) has 3 years of Non-Current Assets data on record, last reported at $5.9 million in Q3 2025.

  • For Q3 2025, Non-Current Assets rose 564.42% year-over-year to $5.9 million; the TTM value through Sep 2025 reached $24.6 million, up 190.32%, while the annual FY2024 figure was $6.5 million, 141.01% up from the prior year.
  • Non-Current Assets reached $5.9 million in Q3 2025 per CTNM's latest filing, down from $6.0 million in the prior quarter.
  • Across five years, Non-Current Assets topped out at $6.5 million in Q4 2024 and bottomed at $891000.0 in Q3 2024.
  • Average Non-Current Assets over 3 years is $4.1 million, with a median of $4.9 million recorded in 2024.
  • The widest YoY moves for Non-Current Assets: up 564.42% in 2025, down 59.1% in 2025.
  • A 3-year view of Non-Current Assets shows it stood at $2.7 million in 2023, then skyrocketed by 141.01% to $6.5 million in 2024, then fell by 8.34% to $5.9 million in 2025.
  • Per Business Quant database, its latest 3 readings for Non-Current Assets were $5.9 million in Q3 2025, $6.0 million in Q2 2025, and $6.1 million in Q1 2025.